Vox Markets Logo

Vadim Alexandre on SkinBioTherapeutics and Alan Green on 4 Stocks

13:11, 24th February 2020

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Vadim Alexandre on SkinBioTherapeutics and Alan Green on 4 Stocks

Vadim Alexandre, Head of Healthcare at SP Angel discusses SkinBioTherapeutics (SBTX) FOLLOW

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain. The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.


Alan Green CEO of Brand Communications talks about:

Tertiary Minerals (TYM) FOLLOW

Watches of Switzerland (WOSG) FOLLOW

JD Sports (JD.) FOLLOW

CVS Group (CVSG) FOLLOW

(Interview starts at 10 minutes 51 seconds)

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Watchlist